Furthermore, the intranodal administration of the IK kinase (IKK) complex-selective peptide inhibitor of the essential modulator-binding domain of NF-kB (NEMO) in canine patients with relapsed B-cell lymphoma was able to inhibit NF-kB expression and reduce tumor burden. Here, NFKB1 is linked to neoplasm.